CY1107715T1 - Διαγνωση και αγωγη του καρκινου του προστατη - Google Patents

Διαγνωση και αγωγη του καρκινου του προστατη

Info

Publication number
CY1107715T1
CY1107715T1 CY20071101073T CY071101073T CY1107715T1 CY 1107715 T1 CY1107715 T1 CY 1107715T1 CY 20071101073 T CY20071101073 T CY 20071101073T CY 071101073 T CY071101073 T CY 071101073T CY 1107715 T1 CY1107715 T1 CY 1107715T1
Authority
CY
Cyprus
Prior art keywords
hne
gated
voltage
nucleic acid
cancer
Prior art date
Application number
CY20071101073T
Other languages
English (en)
Inventor
Mustafa Bilgin Ali Djamgoz
Scott Paton Fraser
James Kenneth Joseph Diss
Original Assignee
Imperial Innovations Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Limited filed Critical Imperial Innovations Limited
Publication of CY1107715T1 publication Critical patent/CY1107715T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Μέθοδος διαγνώσεως του καρκίνου σε έναν ασθενή άνθρωπο περιλαμβάνουσα τα στάδια (i) της λήψεως ενός δείγματος περιέχοντος νουκλεϊνικό οξύ και/ή πρωτεΐνη από τον ασθενή· και (ii) του προσδιορισμού του αν το δείγμα περιέχει ένα επίπεδο νουκλεϊνικού οξέως ή πρωτεΐνης πυροδοτούμενου από τάση διαύλου Na+ hNe-Na σχετιζόμενου με τον καρκίνο. Μέθοδος αγωγής του καρκίνου περιλαμβάνουσα το στάδιο της χορηγήσεως σε έναν ασθενή ενός παράγοντα ο οποίος αποτρέπει επιλεκτικά τη λειτουργία του πυροδοτούμενου από τάση διαύλου Na+ hNe-Na. Γενετικό μόρφωμα περιλαμβάνον ένα νουκλεϊνικό οξύ το οποίο κωδικοποιεί ένα μόριο ικανό να αποτρέπει τη λειτουργία ενός πυροδοτούμενου από τάση διαύλου Na+ hNe-Na εκφραζόμενο σε ένα κύτταρο. Οι μέθοδοι και οι συνθέσεις είναι ιδιαίτερα κατάλληλες για τον καρκίνο του προστάτη.
CY20071101073T 2000-09-02 2007-08-09 Διαγνωση και αγωγη του καρκινου του προστατη CY1107715T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0021617.6A GB0021617D0 (en) 2000-09-02 2000-09-02 Diagnosis and treatment of cancer
EP01960979A EP1313882B1 (en) 2000-09-02 2001-09-03 Diagnosis and treatment of prostate cancer

Publications (1)

Publication Number Publication Date
CY1107715T1 true CY1107715T1 (el) 2013-04-18

Family

ID=9898761

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071101073T CY1107715T1 (el) 2000-09-02 2007-08-09 Διαγνωση και αγωγη του καρκινου του προστατη

Country Status (10)

Country Link
US (2) US20060166194A1 (el)
EP (1) EP1313882B1 (el)
JP (1) JP2004507254A (el)
AT (1) ATE361993T1 (el)
AU (1) AU2001282364A1 (el)
CY (1) CY1107715T1 (el)
DE (1) DE60128368T2 (el)
ES (1) ES2288979T3 (el)
GB (1) GB0021617D0 (el)
WO (1) WO2002018637A2 (el)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002084284A2 (en) * 2001-04-12 2002-10-24 Imperial College Innovations Limited Diagnosis and treatment of cancer:ii
EP1377680B1 (en) * 2001-04-12 2011-10-05 Imperial Innovations Limited Diagnosis and treatment of breast cancer based upon scn5a
WO2005069969A2 (en) * 2004-01-21 2005-08-04 University Of Utah Research Foundation Mutant sodium channel nav1.7 and methods related thereto
US20080090233A1 (en) * 2004-05-27 2008-04-17 The Regents Of The University Of Colorado Methods for Prediction of Clinical Outcome to Epidermal Growth Factor Receptor Inhibitors by Cancer Patients
US8921102B2 (en) 2005-07-29 2014-12-30 Gpb Scientific, Llc Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20080050739A1 (en) 2006-06-14 2008-02-28 Roland Stoughton Diagnosis of fetal abnormalities using polymorphisms including short tandem repeats
EP2029779A4 (en) 2006-06-14 2010-01-20 Living Microsystems Inc HIGHLY PARALLEL SNP GENOTYPING UTILIZATION FOR FETAL DIAGNOSIS
EP2589668A1 (en) 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
US8137912B2 (en) 2006-06-14 2012-03-20 The General Hospital Corporation Methods for the diagnosis of fetal abnormalities
JP5745272B2 (ja) * 2007-11-19 2015-07-08 ジェネンテック， インコーポレイテッド 腫瘍進行を阻害するための組成物及び方法
GB0811360D0 (en) * 2008-06-20 2008-07-30 Imp Innovations Ltd Methods
PT2562268T (pt) 2008-09-20 2017-03-29 Univ Leland Stanford Junior Diagnóstico não invasivo de aneuploidia fetal por sequenciação
US20120283116A1 (en) 2009-09-11 2012-11-08 Leppert Mark F Mutant Sodium Channel Nav1.7 and Methods Related Thereto
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
US10344060B2 (en) 2013-03-12 2019-07-09 Amgen Inc. Potent and selective inhibitors of Nav1.7
US9636418B2 (en) 2013-03-12 2017-05-02 Amgen Inc. Potent and selective inhibitors of NAV1.7
CR20200626A (es) * 2018-06-22 2021-02-22 Hoffmann La Roche Oligonucleótidos para modular la expresión de scn9a

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU697465B2 (en) * 1994-11-02 1998-10-08 Research Foundation Of The State University Of New York, The Peripheral nervous system specific sodium channels, DNA encoding therefor, crystallization, x-ray diffraction, computer molecular modeling, rational drug design, drug screening, and methods of making and using thereof
US6686193B2 (en) * 2000-07-10 2004-02-03 Vertex Pharmaceuticals, Inc. High throughput method and system for screening candidate compounds for activity against target ion channels

Also Published As

Publication number Publication date
ATE361993T1 (de) 2007-06-15
DE60128368D1 (de) 2007-06-21
EP1313882B1 (en) 2007-05-09
JP2004507254A (ja) 2004-03-11
WO2002018637A3 (en) 2002-11-21
US7759078B2 (en) 2010-07-20
AU2001282364A1 (en) 2002-03-13
DE60128368T2 (de) 2008-01-10
US20060166194A1 (en) 2006-07-27
US20080145859A1 (en) 2008-06-19
GB0021617D0 (en) 2000-10-18
EP1313882A2 (en) 2003-05-28
ES2288979T3 (es) 2008-02-01
WO2002018637A2 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
CY1107715T1 (el) Διαγνωση και αγωγη του καρκινου του προστατη
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
MXPA02011656A (es) Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos.
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
WO2000037643A3 (en) Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
DE60131257D1 (de) Diffusionsbildgebung von gewebe
WO2004110345A3 (en) Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same
ATE402262T1 (de) Verfahren und zusammensetzungen, die eine stearoyl-coa desuturase-hscd5 verwenden
ATE413881T1 (de) Verfahren und zubereitungen um resistenz gegen biologische oder chemische therapien zu überwinden
DK1444516T3 (da) Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
ATE350662T1 (de) Markerproteine für prostatakrebs
Seebauer et al. Effects of cold physical plasma on oral lichen planus: an in vitro study (effects of CAP on OLP)
DK2182064T3 (da) Gen udtrykt i prostatakræft
WO2000009754A3 (en) HUMAN STEAROYL-CoA DESATURASE-RELATED COMPOSITIONS AND METHODS FOR TREATING SKIN DISORDERS
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
CY1110535T1 (el) Μεταλλαξεις του γονιδιου της παρκινης, συνθεσεις, μεθοδοι και χρησεις
BRPI0407213A (pt) Método de emprego da elevação de marinobufagenina na determinação da presença de pré-eclampsia e aparelhos relacionados
DE69920681D1 (de) Humaner k+ ionenkanal und therapeutische verwendungen davon
BR0312483A (pt) Anticorpos e seus usos
Lukacova et al. Relationship between radiobiological hypoxia in a C3H mouse mammary carcinoma and osteopontin levels in mouse serum
Iroanya et al. Messenger RNA (mRNA)-based age determination using skin-specific markers of saliva epithelial cells
BR9910752A (pt) Métodos e meios para prevenção de cáries e detecção de susceptibilidade
Garcia et al. Can Exercise Training Alter Human Skeletal Muscle DNA Methylation? Metabolites 2022, 12, 222